Product Code: GMDHC07196CDB
Summary
Global Markets Direct's, 'Molecular Partners AG - Product Pipeline Review - 2015', provides an overview of the Molecular Partners AG's pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Partners AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Molecular Partners AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Molecular Partners AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Molecular Partners AG's pipeline products
Reasons to buy
- Evaluate Molecular Partners AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Molecular Partners AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Molecular Partners AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Molecular Partners AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Partners AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Molecular Partners AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Molecular Partners AG Snapshot
- Molecular Partners AG Overview
- Key Information
- Key Facts
- Molecular Partners AG - Research and Development Overview
- Key Therapeutic Areas
- Molecular Partners AG - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Pipeline Products - Out-Licensed Products
- Out-Licensed Products/Combination Treatment Modalities
- Molecular Partners AG - Pipeline Products Glance
- Molecular Partners AG - Clinical Stage Pipeline Products
- Phase I Products/Combination Treatment Modalities
- Molecular Partners AG - Early Stage Pipeline Products
- Preclinical Products/Combination Treatment Modalities
- Discovery Products/Combination Treatment Modalities
- Molecular Partners AG - Drug Profiles
- MP-0250
- Product Description
- Mechanism of Action
- R&D Progress
- MP-0274
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Protein 1 for Cancer
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Protein 2 for cancer
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Proteins 1 for Ophthalmology
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Proteins 2 for Ophthalmology
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Proteins 3 for Ophthalmology
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Proteins 4 for Opthalmology
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Proteins 5 for Ophthalmology
- Product Description
- Mechanism of Action
- R&D Progress
- Molecular Partners AG - Pipeline Analysis
- Molecular Partners AG - Pipeline Products by Target
- Molecular Partners AG - Pipeline Products by Route of Administration
- Molecular Partners AG - Pipeline Products by Molecule Type
- Molecular Partners AG - Pipeline Products by Mechanism of Action
- Molecular Partners AG - Locations And Subsidiaries
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Molecular Partners AG, Key Information
- Molecular Partners AG, Key Facts
- Molecular Partners AG - Pipeline by Indication, 2015
- Molecular Partners AG - Pipeline by Stage of Development, 2015
- Molecular Partners AG - Monotherapy Products in Pipeline, 2015
- Molecular Partners AG - Out-Licensed Products in Pipeline, 2015
- Molecular Partners AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
- Molecular Partners AG - Phase I, 2015
- Molecular Partners AG - Preclinical, 2015
- Molecular Partners AG - Discovery, 2015
- Molecular Partners AG - Pipeline by Target, 2015
- Molecular Partners AG - Pipeline by Route of Administration, 2015
- Molecular Partners AG - Pipeline by Molecule Type, 2015
- Molecular Partners AG - Pipeline Products by Mechanism of Action, 2015
List of Figures
- Molecular Partners AG - Pipeline by Top 10 Indication, 2015
- Molecular Partners AG - Pipeline by Stage of Development, 2015
- Molecular Partners AG - Monotherapy Products in Pipeline, 2015
- Molecular Partners AG - Out-Licensed Products in Pipeline, 2015
- Molecular Partners AG - Pipeline by Top 10 Target, 2015
- Molecular Partners AG - Pipeline by Top 10 Molecule Type, 2015
- Molecular Partners AG - Pipeline Products by Top 10 Mechanism of Action, 2015
